| Description | Valnivudine, a precursor of CF-1743, is an orally effective and highly effective anti-herpes zoster (HZ) nucleoside analogue, a bicyclic nucleoside analogue (BCNA). Valnivudine has antiviral activity and is highly inhibitory against varicella zoster virus (VZV). Valnivudine is rapidly and widely converted into CF-1743 in the body. |
| Synonyms | FV 100, FV100, FV-100 |
| molecular weight | 497.58 |
| Molecular formula | C27H35N3O6 |
| CAS | 956483-02-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. De Clercq E. An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 2. Review. PubMed PMID: 26713268; PubMed Central PMCID: PMC4675811. 2. De SK, Hart JC, Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis. 2015 Dec;28(6):589-95. doi: 10.1097/QCO.0000000000000211. PubMed PMID: 26524331. 3. Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4. Review. PubMed PMID: 23886000. 4. De Clercq E. A cutting-edge view on the current state of antiviral drug development. Med Res Rev. 2013 Nov;33(6):1249-77. doi: 10.1002/med.21281. Epub 2013 Mar 11. Review. PubMed PMID: 23495004. |